1400 Coleman Avenue, Suite D27,  Santa Clara, CA 95050, USA

​​​​Luxena Pharmaceuticals, Inc. © ALL RIGHTS RESERVED

​​LPI-1503 is to prevent and treat nausea and vomiting induced by chemotherapy, radiotherapy or surgery.  The benefits of LPI-1503 includes fast-onset, non-invasive, convenience, enhanced safety and efficacy.

Development Status

* Completed formulation development with excellent stability data.

* Finished animal pharmacokinetics (PK) studies in rats and dogs.

* Secured a simplified 505(b)(2) development pathway for LPI-1503.
     # Received positive responses from FDA through a Type B pre-IND meeting.
     # Established chains of GXP CROs to execute the plans agreed by FDA.

* Granted by FDA an orphan drug designation for one of its indications.